U.S. Capital Wealth Advisors LLC raised its stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 3.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,307 shares of the financial services provider's stock after buying an additional 1,500 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in CME Group were worth $11,109,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the stock. Bank Pictet & Cie Europe AG lifted its stake in shares of CME Group by 29.0% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 86,941 shares of the financial services provider's stock valued at $20,190,000 after purchasing an additional 19,533 shares during the period. Focus Partners Advisor Solutions LLC boosted its position in CME Group by 61.0% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 1,671 shares of the financial services provider's stock worth $388,000 after buying an additional 633 shares during the period. GTS Securities LLC increased its stake in shares of CME Group by 186.2% in the fourth quarter. GTS Securities LLC now owns 3,039 shares of the financial services provider's stock valued at $706,000 after buying an additional 6,566 shares during the period. Putney Financial Group LLC bought a new stake in CME Group during the fourth quarter valued at $389,000. Finally, Ascent Group LLC raised its stake in CME Group by 22.8% during the 4th quarter. Ascent Group LLC now owns 16,969 shares of the financial services provider's stock worth $3,941,000 after buying an additional 3,147 shares during the period. 87.75% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on CME shares. Wall Street Zen cut shares of CME Group from a "hold" rating to a "sell" rating in a research report on Sunday, July 13th. UBS Group dropped their target price on shares of CME Group from $305.00 to $285.00 and set a "neutral" rating on the stock in a research report on Monday, September 8th. Oppenheimer raised their price target on shares of CME Group from $300.00 to $303.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Piper Sandler raised their price target on shares of CME Group from $283.00 to $296.00 and gave the stock an "overweight" rating in a research note on Tuesday, July 15th. Finally, Barclays set a $298.00 price target on shares of CME Group and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. Four investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, CME Group has a consensus rating of "Hold" and a consensus price target of $260.60.
Read Our Latest Stock Analysis on CME
Insider Buying and Selling at CME Group
In other CME Group news, insider Timothy Francis Mccourt sold 379 shares of the business's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $259.83, for a total value of $98,475.57. Following the transaction, the insider owned 9,508 shares in the company, valued at approximately $2,470,463.64. The trade was a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William R. Shepard acquired 256 shares of the firm's stock in a transaction on Wednesday, June 25th. The stock was purchased at an average price of $270.53 per share, for a total transaction of $69,255.68. Following the transaction, the director directly owned 258,196 shares of the company's stock, valued at approximately $69,849,763.88. This trade represents a 0.10% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 13,043 shares of company stock valued at $3,527,956. Company insiders own 0.30% of the company's stock.
CME Group Price Performance
Shares of NASDAQ CME traded down $0.45 during mid-day trading on Monday, reaching $261.08. 1,143,012 shares of the company were exchanged, compared to its average volume of 1,903,585. CME Group Inc. has a 52 week low of $212.60 and a 52 week high of $290.79. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $94.09 billion, a PE ratio of 25.27, a PEG ratio of 4.73 and a beta of 0.43. The company's 50 day moving average price is $271.66 and its 200 day moving average price is $270.86.
CME Group (NASDAQ:CME - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.91 by $0.05. The company had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.68 billion. CME Group had a net margin of 58.48% and a return on equity of 14.60%. The firm's revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.56 EPS. Sell-side analysts forecast that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.
CME Group Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 25th. Shareholders of record on Tuesday, September 9th will be paid a $1.25 dividend. The ex-dividend date of this dividend is Tuesday, September 9th. This represents a $5.00 annualized dividend and a yield of 1.9%. CME Group's payout ratio is currently 48.40%.
CME Group Company Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Featured Stories

Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.